Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerebiome
- Development stage
- Phase 4
- Lead developer
- Lallemand Health Solutions
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Cerebiome is a proprietary psychobiotic formulation developed by Lallemand Health Solutions, consisting of two specific probiotic strains: *Lactobacillus helveticus* Rosell-52 and *Bifidobacterium longum* Rosell-175. It is specifically designed to target the gut-brain axis to support mental health, particularly in the management of stress, anxiety, and depression. The product works by modulating the hypothalamic-pituitary-adrenal (HPA) axis to reduce cortisol levels, decreasing systemic pro-inflammatory cytokines (such as TNF-alpha and IL-6), and promoting the production of neuroprotective factors. It is one of the most extensively researched probiotic combinations for mood disorders, with clinical evidence supporting its use as both a standalone supplement and an adjunct to conventional antidepressant therapy.
- Brand names
- CerebiomeProbio'StickProbioStick
- Other names
- Lactobacillus helveticus Rosell-52 + Bifidobacterium longum Rosell-175L. helveticus R0052 + B. longum R0175
Beyond the preview
Go deeper on Cerebiome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cerebiome.